Lymphoma

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
Wei Liu, Hesong Zou, Lianting Chen, Wenyang Huang, Rui Lv, Yan Xu, Huimin Liu, Yin Shi, Kefei Wang, Yi Wang, Wenjie Xiong, Shuhui Deng, Shuhua Yi, Weiwei Sui, Guangxin Peng, Yueshen Ma, Huijun Wang, Lulu Lv, Jianxiang Wang, Jun Wei, Lugui Qiu, Wenting Zheng, Dehui Zou

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008857; DOI: 10.1136/jitc-2024-008857
Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy
Hesong Zou, Wei Liu, Xiaojuan Wang, Yi Wang, Chunyang Wang, Chen Qiu, Huimin Liu, Dandan Shan, Ting Xie, Wenyang Huang, Weiwei Sui, Shuhua Yi, Gang An, Yan Xu, Tonghui Ma, Jianxiang Wang, Lugui Qiu, Dehui Zou

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008450; DOI: 10.1136/jitc-2023-008450
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
Michael Winkelmann, Viktoria Blumenberg, Kai Rejeski, Christina Quell, Veit Bücklein, Maria Ingenerf, Marcus Unterrainer, Christian Schmidt, Franziska J Dekorsy, Peter Bartenstein, Jens Ricke, Michael von Bergwelt-Baildon, Marion Subklewe, Wolfgang G Kunz

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e006659; DOI: 10.1136/jitc-2022-006659
Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report
Christian Koch, Juliane Fleischer, Todor Popov, Karl Frontzek, Bettina Schreiner, Patrick Roth, Markus G. Manz, Simone Unseld, Antonia M. S. Müller, Norman F. Russkamp

Journal for ImmunoTherapy of Cancer Jan 2023, 11 (1) e006059; DOI: 10.1136/jitc-2022-006059
T-cell lymphoma secondary to checkpoint inhibitor therapy
Kartik Anand, Joe Ensor, Sai Ravi Pingali, Patrick Hwu, Madeleine Duvic, Stephen Chiang, Roberto Miranda, Youli Zu, Swaminathan Iyer

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000104; DOI: 10.1136/jitc-2019-000104
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
Marisa O Peluso, Ammar Adam, Caroline M Armet, Li Zhang, Rachel W O’Connor, Benjamin H Lee, Andrew C Lake, Emmanuel Normant, Scott C Chappel, Jonathan A Hill, Vito J Palombella, Pamela M Holland, Alison M Paterson

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000413; DOI: 10.1136/jitc-2019-000413
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers
Laura Marconato, Luca Aresu, Damiano Stefanello, Stefano Comazzi, Valeria Martini, Roberta Ferrari, Fulvio Riondato, Nicole Rouquet, Patrick Frayssinet, Silvia Sabattini

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 146; DOI: 10.1186/s40425-019-0624-y
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Michael Boyiadzis, Michael R. Bishop, Rafat Abonour, Kenneth C. Anderson, Stephen M. Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen Van Besien, P. Leif Bergsagel, Ivan Borrello, Joshua Brody, Jill Brufsky, Mitchell Cairo, Ajai Chari, Adam Cohen, Jorge Cortes, Stephen J. Forman, Jonathan W. Friedberg, Ephraim J. Fuchs, Steven D. Gore, Sundar Jagannath, Brad S. Kahl, Justin Kline, James N. Kochenderfer, Larry W. Kwak, Ronald Levy, Marcos de Lima, Mark R. Litzow, Anuj Mahindra, Jeffrey Miller, Nikhil C. Munshi, Robert Z. Orlowski, John M. Pagel, David L. Porter, Stephen J. Russell, Karl Schwartz, Margaret A. Shipp, David Siegel, Richard M. Stone, Martin S. Tallman, John M. Timmerman, Frits Van Rhee, Edmund K. Waller, Ann Welsh, Michael Werner, Peter H. Wiernik, Madhav V. Dhodapkar

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 90; DOI: 10.1186/s40425-016-0188-z
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Michael M. Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June, Michael R. Bishop

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 137; DOI: 10.1186/s40425-018-0460-5
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina Piha-Paul, Murali V. P. Nadella, Xiaokun Xiao, Jeff Hsu, Alexey Revenko, Brett P. Monia, A. Robert MacLeod, David S. Hong

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 119; DOI: 10.1186/s40425-018-0436-5

Main menu

Lymphoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Lymphoma

Pages